ArticleHereditas2025
The use of polyphenols extracted from Chinese sweet leaf tea (Rubus suavissimus S. Lee.) as novel drugs for the treatment of metabolic dysfunction associated steatotic liver disease.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMetabolic dysfunction associated steatotic liver disease (MASLD) is a pressing global health issue with limited treatment options. Chinese sweet leaf tea (CSLT), rich in polyphenols, shows promise in addressing MASLD due to its anti-inflammatory, obesity-reducing, and metabolic-regulating properties. This study aimed to explore the therapeutic potential of CSLT polyphenols for MASLD treatment.
methodsA comprehensive approach combining bioinformatics, network pharmacology, molecular docking, high-throughput sequencing, and experimental validation was employed. CSLT extracts were screened for active compounds, and potential targets associated with MASLD were predicted. A protein-protein interaction network was constructed to identify key regulators of lipid metabolism. Molecular docking studies validated interactions between core polyphenols and MASLD-related targets. In vitro studies using HepG2 cells and in vivo studies in a high-fat diet-induced rat model were conducted to assess the efficacy of polyphenol-rich CSLT extract (PE-CSLT) in ameliorating MASLD symptoms.
resultsA total of Eighty-two chemical constituents were initially identified in CSLT. Twenty-six active compounds were screened in CSLT extracts, targeting one hundred and six proteins related to twenty MASLD-associated genes. PE-CSLT demonstrated significant efficacy in reducing body weight gain, serum lipid levels, and liver fat accumulation in MASLD rats. Gene expression analysis revealed modulation of key metabolic regulators, including SREBP1, ACACA, AMPK, and PPARα. Molecular docking confirmed strong binding of eleven PE-CSLT components to these targets. Our findings highlight the therapeutic potential of PE-CSLT for MASLD, providing a scientific basis for its development as a novel drug.
conclusionThis study underscores the promise of natural products in modern medicinal practices and emphasizes the need for further clinical evaluation of PE-CSLT in MASLD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.